OBJECTIVES: To study the feasibility of an optimized multiphase renal-CT-angiography (MP-CTA) protocol in patients with history of renal transplantation compared with Doppler-ultrasound (DUS). METHODS: 36 Patients underwent both DUS and time-resolved, MP-CTA (12 phases), with a mean contrast-volume of 34.4±5.1 ml. Quality of MP-CTA was assessed quantitatively (vascular attenuation) and qualitatively (grades 1-4, 1=best). For the assessment of clinical value of MP-CTA, cases were grouped into normal, macrovascular (arterial/venous) and microvascular complications (parenchymal perfusion defect). DUS served as the standard of reference. RESULTS: Using the best of 12 phases in each patient, optimal attenuation was 353±111 HU, 337±98 HU and 164±51 HU in the iliac arteries, renal arteries, and renal veins, respectively. Mean image quality was 1.1±0.3 (n=36) and 2.1±0.6 (n=30) for the transplant renal arteries and veins, respectively. Six renal veins were non-diagnostic in MP-CTA. In 36 patients, MP-CTA showed 13 vascular complications and 10 parenchymal perfusion defects. DUS was not assessable in eight patients. Overall, MP-CTA showed 15 cases with pathology (42%) not identifiable with DUS. The mean effective radiation dose of the MP-CTA protocol was 13.5±5.2 mSv. CONCLUSION: MP-CTA can be sufficiently performed with reduced contrast volume at reasonable radiation dose in renal transplant patients, providing substantially higher diagnostic yield than DUS.
OBJECTIVES: To study the feasibility of an optimized multiphase renal-CT-angiography (MP-CTA) protocol in patients with history of renal transplantation compared with Doppler-ultrasound (DUS). METHODS: 36 Patients underwent both DUS and time-resolved, MP-CTA (12 phases), with a mean contrast-volume of 34.4±5.1 ml. Quality of MP-CTA was assessed quantitatively (vascular attenuation) and qualitatively (grades 1-4, 1=best). For the assessment of clinical value of MP-CTA, cases were grouped into normal, macrovascular (arterial/venous) and microvascular complications (parenchymal perfusion defect). DUS served as the standard of reference. RESULTS: Using the best of 12 phases in each patient, optimal attenuation was 353±111 HU, 337±98 HU and 164±51 HU in the iliac arteries, renal arteries, and renal veins, respectively. Mean image quality was 1.1±0.3 (n=36) and 2.1±0.6 (n=30) for the transplant renal arteries and veins, respectively. Six renal veins were non-diagnostic in MP-CTA. In 36 patients, MP-CTA showed 13 vascular complications and 10 parenchymal perfusion defects. DUS was not assessable in eight patients. Overall, MP-CTA showed 15 cases with pathology (42%) not identifiable with DUS. The mean effective radiation dose of the MP-CTA protocol was 13.5±5.2 mSv. CONCLUSION: MP-CTA can be sufficiently performed with reduced contrast volume at reasonable radiation dose in renal transplant patients, providing substantially higher diagnostic yield than DUS.
Authors: A Helck; M Wessely; M Notohamiprodjo; U Schönermarck; E Klotz; M Fischereder; F Schön; K Nikolaou; D A Clevert; M Reiser; C Becker Journal: Eur Radiol Date: 2013-05-10 Impact factor: 5.315
Authors: Andreas Helck; Ulf Schönermarck; Antje Habicht; Mike Notohamiprodjo; Manfred Stangl; Ernst Klotz; Konstantin Nikolaou; Christian la Fougère; Dirk Andrè Clevert; Maximilian Reiser; Christoph Becker Journal: PLoS One Date: 2014-03-11 Impact factor: 3.240